BioLineRx Ltd.
BLRX
$4.24
-$0.33-7.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 22.34M | 28.94M | 21.99M | 17.05M | 11.66M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.34M | 28.94M | 21.99M | 17.05M | 11.66M |
| Cost of Revenue | 7.84M | 9.26M | 6.87M | 6.04M | 5.15M |
| Gross Profit | 14.50M | 19.68M | 15.13M | 11.00M | 6.51M |
| SG&A Expenses | 22.94M | 29.68M | 32.58M | 35.27M | 34.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.06M | 48.09M | 49.84M | 51.86M | 50.61M |
| Operating Income | -16.72M | -19.15M | -27.85M | -34.82M | -38.96M |
| Income Before Tax | -3.40M | -9.22M | -19.92M | -30.12M | -49.15M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.40 | -9.22 | -19.92 | -30.12 | -49.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.40M | -9.22M | -19.92M | -30.12M | -49.15M |
| EBIT | -16.72M | -19.15M | -27.85M | -34.82M | -38.96M |
| EBITDA | -14.00M | -15.70M | -24.99M | -32.57M | -36.99M |
| EPS Basic | 0.00 | -0.01 | -0.02 | -0.03 | -0.05 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | -0.02 | -0.03 |
| EPS Diluted | 0.00 | -0.01 | -0.02 | -0.03 | -0.05 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | -0.02 | -0.03 |
| Average Basic Shares Outstanding | 5.92B | 4.79B | 4.56B | 4.29B | 4.02B |
| Average Diluted Shares Outstanding | 5.92B | 4.79B | 4.56B | 4.29B | 4.02B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |